Summary: Apnimed, a medical-stage pharmaceutical enterprise, has done early enrollment for its LunAIRo stage 3 research, assessing the efficacy and safety of its direct candidate Advert109 for managing obstructive sleep apnea (OSA). Advertisement109, a probable very first oral … [Read more...]
NIH Long COVID Sleep Trials to Begin Enrollment Soon
Summary: The NIH’s Recover Initiative is launching medical trials to investigate treatments for long COVID-relevant signs and symptoms, together with rest disturbances and write-up-exertional malaise. The Recuperate-Sleep trials will study two Fda-accredited medication, … [Read more...]
LivaNova Concludes Enrollment in OSA Neurostimulator Trial
Summary: LivaNova announces completion of enrollment in the OSPREY trial for its aura6000 System, an implantable neurostimulator designed to address moderate to severe obstructive sleep apnea. The system, already CE marked, aims to maintain upper airway muscle tone, reducing or … [Read more...]
Sleep Apnea Neurostimulator Study to Conclude Enrollment Early
LivaNova PLC announced that its OSPREY clinical research evaluating the aura6000 hypoglossal nerve stimulation program in individuals with obstructive rest apnea reached a good predictive consequence and will conclude enrollment before than predicted. This suggests there is a … [Read more...]